PHIA Koninklijke Philips N.V.

Philips and Leeds Teaching Hospitals NHS Trust to set new standards for specialist integrated cardiac care

Philips and Leeds Teaching Hospitals NHS Trust to set new standards for specialist integrated cardiac care

June 25, 2020 

Seven-year agreement puts patients at heart of service design to support increased excellence across specialist care, research and local care provision

Amsterdam, the Netherlands and Guildford, UK – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Leeds Teaching Hospitals NHS Trust today announced a seven-year managed service agreement to deliver on the Trusts’ vision to set new standards of excellence for cardiac care in the UK and globally. The partnership will combine the latest innovations in technology for integrated cardiovascular solutions to deliver on the quadruple aim: better health outcomes, lower cost of care, and an improved experience for patients and staff. The service improvement program will support the co-design of new patient pathways and workflows, all with the aim of delivering the best care experience for patients.

“The Cardiology team at Leeds Teaching Hospitals are very proud of the quality of cardiac care we are able to deliver for our patients,” said Dr Chris Pepper, Clinical Director for Cardiology at Leeds Teaching Hospitals NHS Trust. “We see this partnership as a hugely exciting and positive opportunity to improve this further. We look forward to being able to provide state-of-the-art cardiac imaging as part of a highly efficient and forward-looking cardiology service for the people of Leeds and West Yorkshire. We also look forward to a positive and collaborative working relationship with Philips.”

The agreement includes six fully featured interventional cardiac suites based on the Philips Azurion platform, including two specialized electrophysiology suites and a structural heart suite, as well as advanced patient monitoring and ultrasound systems. The Azurion platform provides an intuitive, seamless approach for minimally invasive procedures that will support Leeds’ clinicians to focus on treating the patient, and its administrators as they strive to improve productivity and efficiency through intelligent resource management.

Dr Pepper continued, “We are now working through the backlog of patients and other challenges created by the COVID-19 pandemic. We need to keep services running and have been supported through our partnership with Philips including in reorganizing lab allocations and maintaining patient flow, which has been of substantial benefit. Our cath labs are an essential part of our operations, so when two of our systems recently needed urgent repair, we were happy that Philips was able to resolve the issues without impact on our daily workflow. Our state-of-the-art ultrasound systems have also helped us maintain efficiency after the first wave of COVID-19 patients and will help streamline and facilitate further recovery.”

"Cardiovascular disease is one of the world’s leading causes of death [1] and in the UK we are now seeing more people dying of heart disease at younger ages than in previous years,” said Neil Mesher, General Manager of Philips UK & Ireland. “The COVID-19 pandemic has shown what we can achieve when we combine our collective resources to combat an urgent, complex challenge. It’s with this spirit that we look forward to working side-by-side with Leeds Teaching Hospitals NHS Trust to improve the region’s cardiac health.”

Leeds Cardiac Clinical Services Unit sees over 25,000 patients a year and offers specialist cardiology services to a regional UK population of over 5.4 million across West Yorkshire. As both a local care provider and international specialism centre, the Trust operates an aspirational international innovation programme that not only benefits the local population but also the global cardiology community by developing cutting-edge techniques to meet challenging patient presentations. With both local and international objectives, Leeds has decided to work in partnership with Philips on a long-term basis to ensure these aspirations are met.

[1]

For further information, please contact:

Mark Groves

Philips Global Press Office

Tel:

Email:

Twitter:

Emily Wells-Burr

Philips UK & Ireland

Tel: 5

Email:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .



Attachments

EN
25/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation ...

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of corona...

 PRESS RELEASE

Philips reiterates timing of 2026 outlook

Philips reiterates timing of 2026 outlook December 4, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit gro...

 PRESS RELEASE

Philips expands commercial availability of world’s first real-time AI-...

Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – (NYSE: PHG, AEX: PH...

 PRESS RELEASE

Philips launches Verida, world’s first detector-based spectral CT powe...

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, (NYSE: PHG, AEX: PHIA), a global leader in health techno...

 PRESS RELEASE

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MR...

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at . A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch